Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | TGM2 | P21980 | 5/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600836 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29400961 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL178701 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29401249 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29391986 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29958970 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL25358347 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL178771 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL21462054 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL25356530 | 0.99 | KMT2A (0.59) | KMT2AMDM2TGM2TLR2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 537 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4532531-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | ScinoPharm Taiwan, Ltd. (TW) | 2025-04-09 | — | — | EP | claimed |
| CN-119708197-A | Ruitalu Process for producing peptide | 深圳翰宇药业股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-114685645-B | Synthetic method of somalupeptide | 深圳翰宇药业股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119161446-B | Process for preparing amylin analogues | 杭州诺泰诺和生物医药科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119371515-A | Synthesis method of salmon calcitonin acetylation impurity | 翰宇药业（武汉）有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-119161446-A | Process for preparing amylin analogues | 杭州诺泰诺和生物医药科技有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-117903232-B | Synthesis method of biaryl bridged cyclic peptide | 杭州禾泰健宇生物科技有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-118420598-A | PSMA targeting small molecular probe, radionuclide-labeled PSMA targeting small molecular probe, and preparation methods and applications thereof | 苏州大学 | 2024-08-02 | — | — | CN | claimed |
| CN-118403181-A | Novel multifunctional nano-drug carrier material and preparation method and application thereof | 浙江工业大学 | 2024-07-30 | — | — | CN | claimed |
| CN-117860663-A | Subcutaneous injection crosslinked hydrogel for inhibiting scar and preparation method thereof | 华中科技大学同济医学院附属协和医院 | 2024-04-12 | — | — | CN | claimed |
| US-20230406900-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | SCINOPHARM TAIWAN, LTD. (TW) | 2023-12-21 | — | — | US | claimed |
| WO-2023234860-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | SCINOPHARM TAIWAN LTD. (TW) | 2023-12-07 | — | — | WO | claimed |
| CN-116903495-A | Preparation method of radioactive diagnostic drug ligand | 江苏华益科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-112679602-B | Solid phase synthesis method of cable Ma Lutai | 苏州特瑞药业股份有限公司 | 2023-09-22 | — | — | CN | claimed |
| CN-112010961-B | Solid-liquid synthesis method of somalupeptide | 深圳市健元医药科技有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-115677845-A | Method for preparing somaglutide by dipeptide feeding at specific site | 前沿生物药业(南京)股份有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-114805601-A | Application of polypeptide analogue in anti-wrinkle and anti-aging | 深圳深创生物药业有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114685645-A | Synthetic method of somaglutide | 深圳翰宇药业股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-114634425-A | Novel synthesis process of PSMA inhibitor | 湖北强耀生物科技有限公司 | 2022-06-17 | — | — | CN | claimed |
| CN-114349827-A | Synthetic method of brennuo peptide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2022-04-15 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406900-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | GLP1R, IAPP, GCG | KMT2A 4142/4885MDM2 2682/4885TGM2 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.